Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Novel approach for the drug delivery of L-asparaginase in the treatment of acute lymphoblastic leukemia
EF 2016-17
Résumé
Healthy cells possess an enzyme called asparagine synthetase that generates the amino acid asparagine, which is necessary for protein synthesis and cell survival. Most of Acute Lymphoblastic Leukemia (ALL) cells stop expressing asparagine synthetase, resulting in a reliance on extracellular sources of L-asparagine. L-asparaginase is an established cancer drug for the treatment of ALL that can inhibit cell proliferation and promote cell death by depleting plasma levels of asparagine, starving these cancer cells of a key nutrient. L-asparaginase therapy is subject to high costs, and the possibility of toxicity and immunological responses. Consequently, there is an unmet need for new formulations of L-asparaginase to improve the effectiveness by overcoming these obstacles. In this study, I will evaluate one such new formulation of encapsulated L-asparaginase delivered using a safe, well-tolerated vector previously used in other human therapeutics. Since the L-asparaginase in this formulation is encapsulated, the enzyme should be protected from dilution and degradation, and may have reduced immunogenicity, yet still be able to break down soluble L-asparagine. Consequently, I will investigate if this formulation is a suitable vehicle for achieving reduced costs, increased L-asparaginase half-life, decreased toxicity, and reduced immunological responses of L-asparaginase therapy.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
367141
Name
gynn matthew D
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel approach for the drug delivery of L-asparaginase in the treatment of acute lymphoblastic leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Lymphoblastic Leukemia; Asparaginase; B-All; Cancer; Enzyme Therapy; Leukemia; Pediatrics; Saccharomyces Cerervisiae; Therapeutic Vehicle; Therapeutics
Abstract
Healthy cells possess an enzyme called asparagine synthetase that generates the amino acid asparagine, which is necessary for protein synthesis and cell survival. Most of Acute Lymphoblastic Leukemia (ALL) cells stop expressing asparagine synthetase, resulting in a reliance on extracellular sources of L-asparagine. L-asparaginase is an established cancer drug for the treatment of ALL that can inhibit cell proliferation and promote cell death by depleting plasma levels of asparagine, starving these cancer cells of a key nutrient. L-asparaginase therapy is subject to high costs, and the possibility of toxicity and immunological responses. Consequently, there is an unmet need for new formulations of L-asparaginase to improve the effectiveness by overcoming these obstacles. In this study, I will evaluate one such new formulation of encapsulated L-asparaginase delivered using a safe, well-tolerated vector previously used in other human therapeutics. Since the L-asparaginase in this formulation is encapsulated, the enzyme should be protected from dilution and degradation, and may have reduced immunogenicity, yet still be able to break down soluble L-asparagine. Consequently, I will investigate if this formulation is a suitable vehicle for achieving reduced costs, increased L-asparaginase half-life, decreased toxicity, and reduced immunological responses of L-asparaginase therapy.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
gynn, matthew D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~